|
|
| I Need More Data: Exploring The Potential Of Digital Biomarkers | From The Editor | By Dan Schell, Chief Editor, Clinical Leader | We are still in the early days of uncovering all the advantages of digital biomarkers. “It’s difficult to figure out what you can measure repeatedly and with some sense of validity,” says Bari Kowal, SVP, development operations, portfolio management and biostatistics data management at Regeneron. |
|
|
| The Power And Potential Of RBM In Clinical Trials | Article | By Olubukola Oseni, inSeption Group | Risk-based monitoring increases overall trial oversight by balancing “must-do” data collection and “nice-to-have” data against site and patient burden — and, more importantly, patient safety. |
|
|
CLINICAL DATA MANAGEMENT & ANALYSIS |
|
|
| Validating A Better ALS Biomarker With Coya’s Fred Grossman | Guest Column | A conversation with Fred Grossman, DO, FAPA, Coya Therapeutics | Coya Therapeutics President and CMO Fred Grossman, DO, FAPA discusses a potential new biomarker for ALS — 4-HNE, an oxidative stress biomarker — and how it could be more effective than the current standard, NfL. |
|
|
|
|
| Your Clinical Study Data Is In Good Hands | Video | OCT Clinical | Every pharma company conducts a clinical trial before introducing a new medicine to the market. Learn how to meet study deadlines and stay within budget using an effective data management platform. |
|
|
CHOOSE YOUR OWN ADVENTURE |
|
|
|
| You're receiving the Friday edition of the Clinical Leader newsletter, focusing on Clinical Data Management & Analytics and Trial Monitoring. To make changes to your newsletter selections, update your topic preferences. - Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
- Clinical Trial Technology (Tuesday)
- Decentralized Trials | Trial Management (Wednesday)
- Outsourcing Models | Regulatory & Compliance (Thursday)
- Clinical Data Management & Analytics | Trial Monitoring (Friday)
Learn more about our personalized newsletters here. |
|
|
| Connect With Clinical Leader: |
|
|
|
